Varian, a Siemens Healthineers company, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for new functionality to its Ethos therapy system. Introducing a streamlined workflow for daily treatment adaptation across more areas of the body, and providing greater connectivity to patient data, this latest generation reduces complexity, making it easier to implement adaptive, personalized radiotherapy.

Ethos 2.0 equips clinical teams with a versatile, comprehensive solution, optimizing clinical and operational efficiencies with several new and updated features:

• Enhanced algorithms, driving the Ethos Intelligent Optimization Engine (IOE), provide a more optimized approach to treatment planning and dose delivery, allowing for faster treatment.
• Images acquired using the HyperSight imaging solution, an option on the Ethos system, are now integrated into the software to streamline workflows, enabling direct dose calculation for adapting treatments. This enhancement means clinicians can create a treatment plan based on that day's anatomy more easily and more accurately.
• The system significantly expands the number of AI-segmented anatomical structures that can be automatically contoured, greatly reducing the need for the time-consuming, manual process of contouring by hand. This latest version was expanded to include 70+ structures in the head & neck, thorax, abdomen, pelvis, and bowel regions when using HyperSight images.
• Latest generation optimizes clinical and operational efficiencies by facilitating seamless data sharing and exchange with the ARIA CORE oncology management solution for effective patient management.

"Our latest Ethos system reflects our ongoing commitment to develop innovative solutions that make real-time, adaptive radiotherapy treatment easier to accomplish in any setting," said Arthur Kaindl, Head of Varian. "By reducing workflow complexity, leveraging advanced, AI-powered technology, and enabling greater connectivity to patient data across our ecosystem, we continue to invest in comprehensive tools to help clinicians integrate precision throughout the patient journey."

Since its initial launch in 2019, the Ethos system has become an increasingly valuable radiotherapy tool.  Varian data show that providers who were treating with Ethos chose the adapted treatment plan 88% of the time as more beneficial for the patient. Using a single Ethos system, clinicians can choose between online or offline adaptation – or conventional image-guided radiotherapy (IGRT) – making this a very versatile system.